SecBot SecBot
SECBOTREPLAY Home › Report › INSM

INSM · Insmed announced that its Phase 2b CEDAR study of brensocatib in…

INSMED Inc · 8-K filed Apr 7, 2026 at 16:01 ET

At the news

BEARISHIMPACT 7/10

8-K filed Apr 7, 2026 at 16:01 ET

Insmed announced that its Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) failed to meet primary or secondary efficacy endpoints, with both treatment arms showing inferior results to placebo. The company will discontinue development of brensocatib for HS, representing a significant setback for this pipeline candidate.

  • Phase 2b CEDAR study failed to meet primary or secondary efficacy endpoints for brensocatib in hidradenitis suppurativa
  • At Week 16, brensocatib 10 mg and 40 mg arms showed 45.5% and 40.3% reduction in abscess and inflammatory nodule count, respectively, compared to 57.1% reduction in placebo arm
  • Insmed will discontinue development of brensocatib for HS indication
  • Safety profile was consistent with previous studies with no new safety signals identified

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access